Metoprol

Quick links to important sections

Metoprol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metoprol

Property Description
Active ingredient Metoprolol
Form Tablet (Immediate- and Extended-release), Intravenous solution
Pharmacological class Beta-adrenergic blocking agent (Beta-blocker)
General purpose Cardiovascular stabilization, reducing cardiac workload
Origin Synthetic compound

What Type of Medicine is Metoprolol?

Metoprolol is the active ingredient in preparations like Metoprol, and it is a synthetic compound classified as a beta-adrenergic blocking agent, commonly known as a beta-blocker. This type of medicine is prescription-only. It is used in managing heart conditions and is a cardioselective beta-blocker, meaning it selectively targets the beta1 receptors found primarily in the heart muscle. This selective action is a key differentiator from non-selective beta-blockers. Its essential function is to counteract and limit the stimulating effects of stress hormones like epinephrine on the circulatory system, positioning it as a fundamental anti-hypertensive and anti-arrhythmic agent in cardiovascular medicine.


Understanding Metoprolol's Forms and Composition

The medication is a single active ingredient product available for oral administration as a tablet and for intravenous administration as an injection solution. The active ingredient is supplied as two main salt forms: Metoprolol tartrate and Metoprolol succinate. The choice of salt dictates the medication's release profile; Metoprolol tartrate is formulated for immediate-release tablets, while Metoprolol succinate is engineered as an extended-release tablet (or prolonged-release form). This distinction in formulation provides flexibility in treatment schedules, supporting both short-term intervention and consistent, long-term management.


How Does Metoprolol Generally Affect the Heart?

Metoprolol is classified as a sympatholytic agent because its fundamental mechanism involves blocking the stimulation of the heart by the sympathetic nervous system. This action results in a dual physiological effect that eases the heart's strain: a reduction in the rate of beating (negative chronotropy) and a reduction in the force of muscle contraction (negative inotropy). By achieving a slower heart rate and reducing its pumping effort, the medication significantly lowers the overall workload and oxygen demand on the heart muscle, promoting stabilization of cardiac function.

What side effects are possible with Metoprol?

Possible Side Effects and Safety Information

The official safety profile for metoprolol, the active ingredient in Metoprol, classifies potential adverse reactions based on their expected frequency and the body system affected, according to regulatory standards (e.g., EMA SmPC and FDA labeling).

Common Adverse Reactions

Adverse effects listed as common in official documents (occurring in at least 1 out of 100 people) primarily involve the nervous and cardiovascular systems. These include dizziness, headache, a feeling of fatigue or tiredness, slow heart rate (bradycardia), and orthostatic hypotension (a drop in blood pressure when standing, sometimes resulting in fainting). Gastrointestinal effects such as nausea, diarrhea, constipation, and abdominal pain are also noted as common.

System-Organ Classes and Less Common Effects

Adverse reactions are formally grouped by System-Organ Class. For instance, Psychiatric Disorders may include depression, insomnia, or nightmares. Vascular Disorders include cold extremities and, rarely, gangrene in patients with severe pre-existing circulatory issues. Respiratory Disorders may involve shortness of breath or bronchospasm.

Serious Adverse Reactions and Restrictions

The labeling documents the potential for serious adverse reactions, notably the worsening of heart failure symptoms and the risk of severe bradycardia or heart block. A key safety constraint is the risk associated with discontinuation: the abrupt cessation of chronic metoprolol therapy is officially noted as possibly exacerbating angina pectoris and, in some cases, leading to myocardial infarction. Therefore, discontinuation must be gradual.

Population-Specific Safety Notes

Specific regulatory notes address caution for certain patient populations. For individuals with diabetes, the medication may mask signs of hypoglycemia, specifically tachycardia. Patients with severe hepatic impairment (liver problems) may experience increased drug effects due to slower clearance, and the drug may mask the signs of thyrotoxicosis.

Overdose and Emergency Response

Overdose and when to Seek Help

The metoprolol overdose profile, as documented in official regulatory sources, centers on the risk of severe cardiovascular and neurological manifestations.

Documented Overdose Manifestations

Overdose may present with signs of severe bradycardia (excessively slow heart rate), significant hypotension (low blood pressure), atrioventricular (AV) block, and worsening cardiac failure. Life-threatening outcomes officially documented include cardiogenic shock, cardiovascular collapse, and cardiac arrest. Neurological manifestations may involve convulsions, coma, and other altered levels of consciousness. The official label notes that hypoglycemia is a common manifestation in children.

Emergency Action Required

Regulators mandate that individuals seek immediate medical help and contact a Poison Control Center immediately upon suspected overdose due to the life-threatening potential of these symptoms. The officially described management is symptomatic and supportive. No specific antidote is known. However, supportive interventions described in regulatory guidance include the use of Atropine, Glucagon administration, adrenergic drugs, and the potential need for a temporary cardiac pacemaker. Patients who have ingested extended-release formulations may require prolonged hospital monitoring.

Therapeutic Uses of Metoprol

Quick Facts: Uses of Metoprol

  • Hypertension (High Blood Pressure): Supports the management of high blood pressure.
  • Angina Pectoris: Assists in reducing the frequency of chest pain.
  • Heart Attack (Myocardial Infarction): Used for therapeutic management after a heart attack.
  • Heart Failure: Considered for use in the long-term management of chronic heart failure.

Metoprol is a medication prescribed to support individuals managing certain cardiovascular conditions. Its primary use is in the long-term treatment of hypertension, or high blood pressure, which is an important step in reducing the risk of cardiovascular events.

For patients experiencing angina pectoris (chest pain), Metoprol is a treatment option that may help decrease the occurrence of attacks and contribute to improved functional capacity. The drug is also a component of the treatment regimen following a myocardial infarction (heart attack).

In addition, Metoprol (specifically the extended-release formulation) is indicated for managing chronic heart failure in clinically stable patients, when used alongside other standard therapies. Its therapeutic role is to provide support for the heart's function in this setting.

Patients should consult a healthcare provider for personalized guidance to determine if this medication is appropriate for their specific health needs.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Metoprolol

The official regulatory profile for Metoprolol (Metoprol) strictly defines eligibility based on a patient’s pre-existing conditions and age.

Absolute Contraindications

Use is prohibited for individuals with specific severe cardiovascular conditions, including severe bradycardia, cardiogenic shock, decompensated heart failure, second- or third-degree heart block, or sick sinus syndrome (unless a functional pacemaker is present). The medication is also contraindicated in patients with known hypersensitivity to metoprolol or other beta-blockers.

Age and Special Populations

Metoprolol is established for use in adults. In pediatric patients, use is only established for hypertension in children ≥ 6 years of age (extended-release form); use is not established for those under six. Older adults may require caution and lower initial doses due to the likelihood of diminished organ function.

Conditional Restrictions

Caution is mandated for patients with hepatic impairment, often requiring lower starting doses due to altered clearance. The label also requires caution for use in patients with Diabetes Mellitus (as the drug may mask signs of hypoglycemia) and in those with untreated pheochromocytoma (which requires prior alpha-blockade therapy). Use during pregnancy is restricted to cases where the benefit outweighs the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metoprolol's interaction profile is primarily governed by its metabolism through the CYP2D6 enzyme and its mechanism as a beta-adrenergic blocking agent.


Pharmacokinetic Interactions

Co-administration with strong CYP2D6 enzyme inhibitors, such as quinidine, fluoxetine, paroxetine, and propafenone, is documented to increase metoprolol plasma concentration. Strong inhibitors have been shown in regulatory reports to double the exposure of metoprolol. Individuals classified as poor CYP2D6 metabolizers naturally exhibit several-fold higher plasma concentrations, which heightens the risk of interaction severity. Severe hepatic impairment is also noted to prolong the elimination half-life, impacting pharmacokinetics.


Pharmacodynamic Interactions

Concomitant use with other agents that slow atrioventricular (AV) conduction or decrease heart rate results in additive heart rate lowering effects. This includes digitalis glycosides (e.g., Digoxin) and certain calcium channel blockers like verapamil and diltiazem. Combining Metoprolol with catecholamine-depleting drugs (e.g., reserpine, MAO inhibitors) may similarly lead to marked bradycardia or enhanced hypotension. Patients taking Metoprolol who experience a severe allergic reaction may be unresponsive to the usual doses of epinephrine.


Administration Constraints

A specific timing rule exists for clonidine: Metoprolol must be withdrawn several days before the gradual withdrawal of clonidine, or its introduction delayed for several days after clonidine is stopped. For specific extended-release capsule formulations, co-ingestion with alcohol must be avoided due to a documented risk of rapid drug release.

Mechanism of Action

Metoprolol works by modulating the sympathetic nervous system signaling pathways, primarily within the cardiovascular system, resulting in the modulation of physiological parameters.

Selective beta1-Adrenergic Receptor Blockade

Metoprolol is a selective beta1-adrenergic receptor antagonist that acts by competing with catecholamines (like adrenaline and noradrenaline) for binding sites on beta1 receptors. This antagonism occurs principally on the beta1 receptors found predominantly in the heart's myocardial tissue and conduction system. By occupying these receptors, metoprolol interrupts the signaling cascade involving the Gs-protein and cyclic AMP (cAMP), limiting the sympathetic nervous system's activation of the heart.

Modulation of Cardiac Function and Rate

The blockade of beta1 receptors leads to direct effects on cardiac physiology. It induces a negative chronotropic effect by slowing the firing rate of pacemaker cells in the sinoatrial (SA) node and a negative inotropic effect by reducing calcium influx into the ventricular myocardium. This results in decreased heart rate and force of contraction, attenuating the rate and magnitude of sympathetic response and leading to decreased mechanical effort and myocardial oxygen consumption.

Regulation of Renin Release Pathway

Metoprolol also influences the Renin-Angiotensin-Aldosterone System (RAAS). beta1 receptors are present on the juxtaglomerular cells in the kidneys. By blocking these receptors, metoprolol decreases renin secretion, which is an early molecular step in a cascade that influences systemic vascular resistance and circulatory volume.

Dosage and Administration Information

Metoprolol is administered via the oral route for long-term therapy and as an intravenous (IV) injection for early treatment in acute, supervised hospital settings. Standard administration protocols for its use are dependent on the specific salt form prescribed: Metoprolol tartrate (Immediate-Release or IR) and Metoprolol succinate (Extended-Release or ER).


Administration Scope

The frequency of dosing and its relation to meals are guided by the formulation type. IR tablets are typically taken twice daily or in divided doses, and administration is typically performed with or immediately following meals to ensure reliable absorption. In contrast, ER tablets are designed for once-daily administration and can be taken independently of food.

Instruction Detail
Dosing Schedule (Adults) Initial doses range from 25 mg to 100 mg daily, with maintenance doses reaching up to 450 mg daily for IR and 400 mg daily for ER.
Age-group administration Pediatric patients (ge 6 years) with hypertension begin with a dose of 1 mg/kg once daily, not to exceed 50 mg initially.
Missed-dose rule A missed dose should be taken promptly unless the next scheduled dose is near; it is advised against taking two doses simultaneously.

Special Procedural Conditions

Tablet handling is restricted for the extended-release form, which must not be crushed or chewed. Dosage adjustments for both hypertension and heart failure follow a titration protocol where doses are increased gradually at intervals, typically weekly or every two weeks. When discontinuing Metoprolol therapy, it is recommended that the dose be gradually reduced over a period of 1 to 2 weeks, rather than stopping abruptly. This gradual reduction defines the final procedural step for the medication's overall use protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Metoprol


Research Evidence for Managing High Blood Pressure (Hypertension)

Metoprolol's use in high blood pressure (hypertension) was studied for in large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Research examined key outcomes related to changes in blood pressure readings (both systolic and diastolic pressure). Furthermore, research examined whether the use of the medicine was associated with long-term outcomes related to major cardiovascular events, such as stroke and heart attack. Studies monitored blood pressure measurements and described patterns where measurements were described as different from baseline. Evidence for pediatric patients (specifically children aged 6 to 16 years) with high blood pressure was evaluated in some studies, but data for certain age subgroups or complex cases evidence is limited.


Research Evidence Following a Heart Attack (Myocardial Infarction)

The evidence base for using Metoprolol following a heart attack (myocardial infarction) includes extremely large and rigorous clinical trials. Researchers primarily tracked critical, high-level outcomes, including all-cause mortality (survival) and the rate of non-fatal reinfarction. Research describes patterns where measurements of the long-term rate of reinfarction and mortality were lower for people who continued treatment compared to those who did not. Studies described findings where an early intravenous administration was studied for outcomes related to reinfarction, but concurrently research monitored the occurrence of certain adverse events, like cardiogenic shock, in specific patient groups.


Research Evidence for Chronic Heart Failure

For the long-term management of chronic heart failure, the evidence is primarily anchored by pivotal, large-scale intervention trials, which specifically focused on the extended-release succinate salt formulation. Studies monitored outcomes and described patterns where research monitored patterns related to death and hospitalization rates between the groups assigned to Metoprolol and placebo groups. However, the definitive evidence applies almost entirely to the extended-release salt form. Furthermore, evidence for patients with the most severe form of heart failure (NYHA Class IV) remains limited compared to the data for patients with moderate forms of the condition.


Key Limitations and Areas of Uncertainty

The research base, while substantial, contains areas of uncertainty and limitation. Comparative evidence is lacking for how Metoprolol performs directly against newer classes of drugs for every indication. Finally, research exploring long-term symptom management for angina and certain arrhythmias relies on studies with follow-up durations that were more limited than those used for mortality trials, meaning the certainty remains low for those specific outcomes.

Key Studies & References

  1. Metoprolol Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF): Mortality and Morbidity Results
  2. The COMMIT/CCS-2 Trial: Clopidogrel and Metoprolol in Myocardial Infarction Trial/Second Chinese Cardiac Study
  3. Metoprolol - StatPearls (Overview of Indications and Key Trials)

Frequently Asked Questions (FAQ)

Common questions about Metoprol (FAQ)

Q: How long does Metoprol typically take to start showing an effect?

Official product information indicates that a significant initial effect in blocking the \beta-receptor is generally seen within 1 hour after taking an oral dose. However, the maximum desired blood pressure reduction is generally observed after 1 week of continuous therapy at a given dosage level.

Q: Is a doctor required to gradually reduce the dose when discontinuing Metoprol?

Regulatory documents state that when therapy is discontinued, the dosage should be gradually reduced over a period of 1 to 2 weeks, requiring supervision by a healthcare provider. This gradual reduction process is described in official documents as being necessary to mitigate the risk of adverse cardiac events.

Q: Does Metoprol have the potential to cause depression or mood changes?

Adverse reaction reports mention that this medicine has the potential to cause central nervous system effects. These reported effects include reversible mental depression, emotional lability (rapid changes in emotion), and temporary decreases in cognitive performance.

Q: Is it safe to take over-the-counter pain medications, such as NSAIDs (e.g., ibuprofen), with Metoprol?

Official documents state that certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the blood pressure-lowering effect of Metoprolol. Official guidelines indicate that blood pressure should be monitored more closely if these medicines are taken together.

Q: Is it okay to consume products containing caffeine while taking Metoprol?

According to regulatory and clinical guidance, consuming caffeine may potentially reduce the effectiveness of this medicine. Caffeine acts as a stimulant and may counteract the blood pressure and heart rate lowering effects of the medication.

Q: What should be done if an occasional dose of Metoprol is missed?

If a dose is missed, regulatory instructions state that it may be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the missed dose should be skipped entirely. Official labeling states that two doses should not be taken simultaneously to compensate for a missed dose.

Q: What kind of monitoring (e.g., blood pressure checks, lab work) is typically required while on Metoprol?

Official instructions indicate that the monitoring of physiological parameters is required during therapy. Specifically, the monitoring of heart rate, heart rhythm, and blood pressure is generally necessary, especially during the period when a dose is first being established or adjusted.

Q: What is the term "beta-blocker" mean in simple language?

Metoprol is a synthetic compound classified as a selective \beta1-adrenergic receptor blocker, commonly known as a beta-blocker. This mechanism works by limiting the effects of certain stress hormones, like adrenaline, on the heart. The result is a reduced heart rate and a lower force of heart contraction.

Q: How will I know if Metoprol is actually working if I don't feel any different?

Official information indicates that the medicine’s effectiveness is primarily assessed by measurable physical outcomes. These outcomes include achieving a desired reduction in blood pressure and reducing the frequency of chest pain (angina attacks). The maximum benefit for blood pressure is generally observed after one week of continuous therapy.

Q: Can Metoprol cause extreme tiredness or fatigue that doesn't go away?

Fatigue and tiredness are listed as common adverse reactions in official safety documents. If these effects are extreme or severe, official safety information indicates they may be symptoms of a serious side effect, such as severe bradycardia (very slow heart rate). Official safety information states that any severe or sudden change in condition should be reported.

Q: Is it true that Metoprol can sometimes cause weight gain?

Yes, official reports state that weight gain is a reported adverse reaction in regulatory documents. This specific effect is classified as uncommon in the official adverse reactions section.

Q: Can Metoprol affect sleep patterns, such as causing insomnia or vivid dreams?

Official regulatory documents list specific sleep-related issues as potential adverse reactions. These include sleep disturbances, insomnia, and the occurrence of nightmares.

Q: Does Metoprol have a known risk of sexual side effects or issues with libido?

Official adverse reaction reports list sexual dysfunction and reduced libido (sex drive) as possible side effects. These effects are generally classified as rare in the regulatory documentation.

Q: Is Metoprol known to interact with common prescription antidepressants or mood stabilizers?

Regulatory information highlights that certain antidepressants, like fluoxetine and paroxetine, can interact with this medicine. These agents inhibit the enzyme (CYP2D6) that breaks down Metoprolol, which can lead to increased blood concentrations and potentially a higher risk of side effects.

Q: Does Metoprol interact with natural supplements or herbal products?

Regulators often caution that comprehensive safety data on interactions between prescription medicines and herbal or natural supplements is not always available. It is advised to be mindful of any supplements that affect blood pressure, as some, like Hawthorn, may alter the medicine’s effect.

Q: What are the differences in side effects between the immediate-release and extended-release forms?

The extended-release (ER) form is engineered to release the medicine slowly and consistently over 24 hours, resulting in lower peak blood concentrations compared to the immediate-release (IR) form. This lower peak concentration profile may potentially lead to a reduced risk of side effects that are associated with high peak drug levels.

Q: Are there common over-the-counter cold and flu medications that should be avoided with Metoprol?

Yes, official regulatory information specifies that certain common over-the-counter cold and flu medications should be used with caution. Specifically, decongestants containing ingredients like pseudoephedrine or phenylephrine may counteract the blood pressure-lowering effect and can cause an increase in blood pressure.

Q: Is the effect of the extended-release form noticeable all day?

The extended-release formulation is specifically designed and intended for once-daily administration. Its engineering is purposed to maintain a controlled and predictable therapeutic effect throughout the entire 24-hour dosing interval.

Q: Can Metoprol cause problems for people who have a history of poor circulation?

Official warnings indicate that this medicine may precipitate or aggravate symptoms of arterial insufficiency, which is related to poor circulation, such as Peripheral Vascular Disease (PVD). Furthermore, the feeling of coldness in the hands and feet is listed as a potential adverse reaction.

Q: Is it possible for Metoprol to affect memory or concentration?

Yes, adverse reaction reports include central nervous system effects that can impact mental function. These reported effects include confusion, temporary short-term memory loss, and a decrease in overall cognitive performance.

Q: What symptoms indicate that my dose of Metoprol may be too high?

According to official safety information, symptoms that may suggest a dose is too high or approaching an overdose include a very slow heart rate (severe bradycardia), severe low blood pressure, severe drowsiness, and fainting. These effects are noted in regulatory information as requiring immediate medical attention.

Q: Can the feeling of a 'racing heart' or palpitations still happen while taking Metoprol?

Even though this medicine is used to manage heart rhythm, palpitations (a feeling of a racing or fluttering heart) are listed as a possible adverse reaction in official safety documents.

Q: Why is Metoprol sometimes prescribed in combination with other blood pressure medications?

Official indications for this medicine state that it may be used to treat high blood pressure both alone or in combination with other anti-hypertensive agents. Combination therapy is a common strategy to achieve optimal blood pressure management.

Q: How long do initial side effects usually last while the body adjusts?

Official health guidance suggests that if initial side effects are mild, they may often resolve naturally. These mild effects may typically disappear within a few days or a couple of weeks as the body adjusts to the medicine.

How should Metoprol be stored and disposed of?

Official Storage and Disposal Instructions

Metoprolol tablets and injection must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), according to regulatory labeling. The oral tablets (Metoprolol Succinate) must be stored in a tight, light-resistant container, and all forms must be kept out of the reach of children.

The injectable solution (Metoprolol Tartrate Injection) has additional handling rules: it must be protected from light, kept in its carton until use, and must not be frozen. Any unused portion of the injection must be discarded after use.

For disposal of unused or expired tablets, the official guidance recommends utilizing a drug take-back program. If a take-back program is unavailable, non-flushable medicines like Metoprolol should be mixed with an unpalatable substance and sealed before discarding in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Metoprol found in:

A-Z Index: